The Global Oral Anticoagulant Market is estimated to grow at a significant CAGR during the forecast period. Anticoagulants are medications that are used to treat and prevent embolic occurrence. Vitamin K antagonists like warfarin and phenprocoumon are the most frequent oral anticoagulants. In recent years, non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran and rivaroxaban have gained popularity. Vitamin K antagonists inhibit the enzyme vitamin K epoxide reductase, preventing the active, reduced form of vitamin K from being synthesised in the liver, Protein S.
A full report of Oral Anticoagulant Market is available at: https://www.omrglobal.com/industry-reports/oral-anticoagulant-market
During the projection period, the global anticoagulant industry has enormous expansion. During the forecast period, the rise in the geriatric population, the rise in cardiovascular disorders, and the rise in the demand for surgical procedures would all support the growth of the oral anticoagulant market shares.
Oral anticoagulants, often known as blood thinners, are commonly prescribed by doctors to lessen or prevent blood coagulation during the clotting process. Deep vein thrombosis, atrial fabrication, myocardial infarction, stroke, pulmonary embolism, and other medical diseases have a significant risk of blood clotting. Although warfarin is the most frequent form of anticoagulant on the market, the emergence or availability of other alternatives or types of anticoagulants is becoming more common.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/oral-anticoagulant-market
For Instance, In October 2019, the food and drug administration has approved the indications for the additional disease prevention of venous thromboembolism (VTE) in hospitals to comprehensively treat patients who are at risk of thromboembolic consequences. And in February 2019, Anthos Therapeutics was founded by Novartis AG and Blackstone Life Sciences for the development of cardiovascular medicines and anticoagulants.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segments Covered
o By Product
o By Indication
o By Distribution Channel
- Regions Covered
o North America
o Europe
o Asia-Pacific
o Rest of the world
- Competitive Landscape: AstraZeneca, Plc (UK), Pfizer (US), Boehringer Ingelheim GmbH, Daiichi Sankyo Company Ltd, Abbott Laboratories among other
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Oral Anticoagulants Market Segmentation
By Product
- Novel Oral Anticoagulant
- Warfarin
By Disease Indication
- Atrial Fibrillation (AF)/ Stroke Prevention
- Deep Vein Thrombosis/ Pulmonary Embolism
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
Company Profiles
- AstraZeneca, Plc (UK)
- Pfizer (US)
- Boehringer Ingelheim GmbH
- Daiichi Sankyo Company Ltd
- Abbott Laboratories
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
